Biogen
BIIB
924 hedge funds and large institutions have $58.6B invested in Biogen in 2015 Q3 according to their latest regulatory filings, with 105 funds opening new positions, 407 increasing their positions, 283 reducing their positions, and 150 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 407 | Existing positions reduced: 283
5% less funds holding
Funds holding: 974 → 924 (-50)
29% less funds holding in top 10
Funds holding in top 10: 52 → 37 (-15)
30% less first-time investments, than exits
New positions opened: 105 | Existing positions closed: 150
31% less capital invested
Capital invested by funds: $85.6B → $58.6B (-$27B)
32% less call options, than puts
Call options by funds: $1.22B | Put options by funds: $1.8B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$395M |
| 2 |
SCM
Steadfast Capital Management
New York
|
+$315M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$280M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$274M |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$250M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.71B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.47B |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$520M |
| 4 |
MCM
Marsico Capital Management
Denver,
Colorado
|
-$518M |
| 5 |
DCP
DSM Capital Partners
Palm Beach Gardens,
Florida
|
-$346M |
BIIB Hedge Fund Activity: Q3 2015 in Review
924 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2015, worth a combined $58.6B — down 31% from $85.6B a quarter earlier.
Sellers outnumbered buyers: 150 funds closed out of BIIB and 105 opened new positions — a net loss of 45 holders — while 283 trimmed existing stakes and 407 added.
The largest buyer was Ameriprise, adding an estimated $395M. The largest seller was Fidelity Investments, cutting an estimated $1.71B.
- 924 institutional investors held Biogen (BIIB) as of Q3 2015, down from 974 in Q2 2015.
- Funds reported $58.6B of Biogen stock for Q3 2015, down 31% quarter-over-quarter.
- 105 funds opened new Biogen positions in Q3 2015 and 150 closed out, a net change of -45 holders.
- The largest Biogen buyer in Q3 2015 was Ameriprise, an estimated $395M added.
- The largest Biogen seller in Q3 2015 was Fidelity Investments, an estimated $1.71B sold.
Based on aggregated 13F filings for Q3 2015.